Case Overview

The Parties

The Patent at Issue

This case involved U.S. Patent Application No. 17/012394 (published as US20200407782A1), covering methods of detecting nucleic acids in individual cells and identifying rare cells from large, heterogeneous cell populations. The technology is critical for modern molecular diagnostics and genomics research.

• • Application Number: US17/012394
• • Publication Number: US20200407782A1
• • Technology Area: Nucleic acid detection; single-cell analysis
• • Subject Matter: Methods of detecting nucleic acids in individual cells and identifying rare cells from large, heterogeneous cell populations

The Verdict & Legal Analysis

Outcome

The Federal Circuit **affirmed** the lower determination and the **appeal was dismissed**. No damages award is applicable in this context, as the action involved a challenge to a USPTO administrative decision rather than a damages-seeking infringement suit against a commercial competitor. Injunctive relief was similarly not at issue.

Verdict Cause Analysis

The case was classified as an infringement action in its procedural coding; however, the substance of the dispute — ACD versus the USPTO Director — reflects a patent prosecution or validity challenge escalated to the Federal Circuit. Such cases commonly arise under 35 U.S.C. § 141 (appeal from PTAB decisions) or related administrative review pathways.

The Federal Circuit’s affirmance signals that the appellate panel found no reversible error in the USPTO’s underlying determination regarding patent application US17/012394. In biotechnology patent cases, adverse USPTO determinations frequently turn on issues of:

• Patent-eligible subject matter under 35 U.S.C. § 101 (Mayo/Alice framework as applied to diagnostic methods)
• Obviousness under 35 U.S.C. § 103 based on prior art combinations
• Written description and enablement under 35 U.S.C. § 112 for broad method claims

While the specific legal grounds for affirmance are not detailed in the available case record, the technology area — nucleic acid detection methods in individual cells — has faced significant § 101 scrutiny following Mayo Collaborative Services v. Prometheus Laboratories (2012) and subsequent Federal Circuit decisions tightening eligibility standards for diagnostic and molecular biology method claims.

Legal Significance

This outcome carries meaningful precedential weight for biotech patent prosecution and appellate strategy:

1. § 101 Eligibility Challenges Remain Potent: Method claims tied to nucleic acid detection and cellular analysis continue to face heightened eligibility scrutiny. An affirmance against ACD reinforces that applicants must carefully draft claims to integrate patent-eligible applications — not merely natural phenomena or abstract analytical steps.
2. Appellate Affirmances Reflect Deference Standards: The Federal Circuit generally affords deference to PTAB factual findings under the substantial evidence standard, making reversals of USPTO determinations difficult to achieve absent clear legal error.
3. Single-Cell Analysis Patent Landscape: This case adds to a growing body of Federal Circuit guidance on molecular diagnostics patents — guidance that in-house counsel and patent agents in genomics must actively monitor.

Strategic Takeaways

For Patent Holders and Prosecutors:

Draft method claims with concrete, application-specific limitations that distinguish natural phenomena. Consider including dependent claims targeting specific detection platforms, reagent configurations, or clinical use contexts to reinforce eligibility.

For Accused Infringers and USPTO Respondents:

This affirmance demonstrates the Federal Circuit’s consistent posture in upholding USPTO determinations when properly supported. Anticipate deference to PTAB findings in briefing strategy.

For R&D Teams:

Freedom-to-operate (FTO) analyses in single-cell sequencing, spatial genomics, and nucleic acid detection should account for both granted patents and pending applications undergoing USPTO review — including those in appeal.